Eric J. Ende's most recent trade in Avadel Pharmaceuticals plc - ADR was a trade of 30,000 Ordinary Shares done at an average price of $7.8 . Disclosure was reported to the exchange on Jan. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avadel Pharmaceuticals plc... | Eric J. Ende | Director | Purchase of securities on an exchange or from another person at price $ 7.84 per share. | 13 Jan 2025 | 30,000 | 208,900 (0%) | 0% | 7.8 | 235,218 | Ordinary Shares |
| Avadel Pharmaceuticals plc... | Eric J. Ende | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Avadel Pharmaceuticals plc... | Eric J. Ende | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2024 | 11,000 | 178,900 (0%) | 0% | 0 | Ordinary Shares | |
| NeuBase Therapeutics Inc | Eric J. Ende | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 37,600 | 37,600 | - | - | Stock option (right to buy) | |
| NeuBase Therapeutics Inc | Eric J. Ende | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 165,803 | 165,803 | - | - | Stock option (right to buy) |